TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00557648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for children
Description: CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
Study: NCT04049786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 25mg
Description: Single-dose of carvedilol 25 mg are being administrated orally.
Study: NCT00557648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for children plus parent training
Description: CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
Study: NCT00547820

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urinary sensor
Study: NCT04308343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Drugs to treat undisturbed ectopic pregnancies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Drugs to treat undisturbed ectopic pregnancies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrotide
Description: Drugs to treat undisturbed ectopic pregnancies
Study: NCT00513643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: 6, 12, 24 U s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: 6, 12, 24 U s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: 6, 12, 24 U s.c.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human regular insulin
Description: 6, 12 and 24 IU sc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human regular insulin
Description: 6, 12 and 24 IU sc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human regular insulin
Description: 6, 12 and 24 IU sc
Study: NCT01296347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
Study: NCT02756273

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bridge device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no bridge device
Study: NCT03881618

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture+auricular pressure,
Description: electroacupuncture+auricular pressure for 20 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture+auricular pressure,
Description: electroacupuncture+auricular pressure for 20 minutes
Study: NCT03824782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy Mask
Description: A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
Study: NCT02197767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1000 mg infusion
Study: NCT03038230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-117 bispecific antibody
Description: MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
Study: NCT00413972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe with simvastatin
Description: Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe with Simvastatin
Description: Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe with Simvastatin
Description: Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for a total of eight weeks
Study: NCT03197779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-962212
Description: Intravenous Infusion administration over 2 hours or 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-962212
Description: Intravenous Infusion administration over 2 hours or 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-962212
Description: Intravenous Infusion administration over 2 hours or 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT04412291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra Prefilled Syringe
Description: A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Prefilled Syringe
Description: 8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care treatment
Description: SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care treatment
Description: SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care treatment
Description: SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)
Study: NCT04320394

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: QuantiFERON Monitor®
Description: The test will be realised to evaluate sepsis induced immunosuppression on patient with septic shock
Study: NCT05998538

Intervention type: PROCEDURE
Intervention: Knee Replacement
Description: Total vs Partial Knee Replacement

Intervention type: PROCEDURE
Intervention: Knee Replacement
Description: Total vs Partial Knee Replacement
Study: NCT01502020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod cream, 3.75%
Description: Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod cream, 3.75%
Description: Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
Study: NCT03329560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral fecal microbiota transplantation
Description: All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
Study: NCT00348855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular drugs strategies
Description: Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance
Description: Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop Smoking
Description: Minimal intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feed Back
Description: Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
Study: NCT02388685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home exercise therapy
Study: NCT01372865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Study: NCT04049786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial blood sampling for PK analysis
Description: Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial blood sampling for PK analysis
Description: Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .
Study: NCT01372865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Study: NCT02216474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study: NCT04049786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial blood sampling for PK analysis
Description: Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .
Study: NCT02216474

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Study: NCT00585195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
Study: NCT03327337

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic Assisted Balloon Tibioplasty
Description: Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Assisted Balloon Tibioplasty
Description: Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
Study: NCT02866539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyherbal capsule coccinia, bougainvillea, catharanthus
Description: A unique combination of 3 herbs that lower blood sugars

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar looking inactive powder
Study: NCT01455857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 is exenatide in DUROS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 is exenatide in DUROS

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ITCA placebo
Description: Formulation in DUROS (no exenatide)
Study: NCT01937156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-01 (Granisetron Transdermal Delivery System)
Description: SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron Hydrochloride Tablet
Description: Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
Study: NCT04386187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSH Foods
Description: The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education about glutathione sources in the diet
Description: Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care nutrition education for type 2 diabetes
Description: The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.
Study: NCT01162317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represents a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acupuncture
Description: Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represent a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes. Each sham or real acupuncture needle will be applied through a tube as sham needles have blunt tip and telescopic shaft, the visual effect and percutaneous sensation of sham needle mimic the real needle penetration.
Study: NCT00096343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT01513577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedicle screws
Description: The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous stab incisions
Description: The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
Study: NCT03855423

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich Fraction (TRF)
Description: TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol
Study: NCT04098757

Intervention type: DIETARY_SUPPLEMENT
Intervention: Migratens
Description: 2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
Study: NCT03456284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic Liver perfusion
Description: The liver grafts will be preserved and evaluated at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase
Study: NCT03573349

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: We will enroll 20 adults (aged 18-65 years) with treatment-resistant depression and will provide two i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), and following ketamine treatment (change biomarkers). This will be an open-label feasibility trial.
Study: NCT00361660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: functional task practice - distributed
Description: This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: functional task practice - condensed
Description: This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
Study: NCT01201733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage
Description: The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy and hot pack
Study: NCT02181387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: administered every 6 hours by mouth up to 4 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00889018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
Study: NCT02314767

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Patients were treated with IPT method, which was an active comparator vs treatment as usual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Patients were treated with IPT method, which was an active comparator vs treatment as usual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Group Therapy
Description: Patients were treated with PeGt method which was an active comparatos vs treatment as usual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Group Therapy
Description: Patients were treated with PeGt method which was an active comparatos vs treatment as usual
Study: NCT01822509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02823366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Study: NCT00611312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
Study: NCT02677480

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test group, probiotic tablets and gel
Description: Effect of probiotic tablets and gel on acidogenic bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group, placebo tablets and gel
Description: Effect of placebo tablets and gel on acidogenic bacteria